Facebook
Twitter
LinkedIn
Forward
MDAnderson APP Onboarding Program - Oncology 102
Oncology 102: An In-Depth Hematology and Oncology Review for Advanced Practice Providers (On-Demand) Winter 2024
The demand for cancer care is expected to increase by 40% over the next six years; however, ASCO is projecting a shortage of more than 2,200 oncologists by 2025. To meet the cancer care needs of all patients, advanced practice providers (APPs), whose education and training focus on health promotion, disease prevention, and primary care medical management, have been increasingly sought-after to fill this shortage. However, many new APPs have little background and training in oncology. As a result, oncology practices need to provide new staff with an onboarding program to help further their knowledge of hematology and oncology.
To assist APPs in their new careers in oncology-based practices, Horizon CME, in partnership with APAO, has developed “Oncology 102: An In-Depth Hematology and Oncology Review for Advanced Practice Providers.” In this two-and-a-half-day virtual program, clinicians will gain a greater understanding of cancer treatment, cancer therapies, side effects, supportive care strategies, palliative care, and more. Expert faculty will provide a detailed review of treatment strategies for hematologic disorders and solid malignancies. Participation in the program will allow APPs to build upon the foundational knowledge acquired in Oncology 101 and provide APPs with a deeper understanding of the cancer treatment strategies they need to support and care for cancer patients as part of the multidisciplinary oncology care team.
Learning Objectives.
- Outline strategies for the treatment of common solid and hematologic malignancies
- Summarize the role of genetics and molecular testing in cancer care
- Implement palliative care and pain management strategies for patients with cancer
- Discuss strategies for the administration and management of chemotherapy
- Identify and appropriately manage immune-related adverse events
- Recognize and treat the adverse effects associated with radiation oncology
Target Audience
This activity is intended for oncology nurse practitioners, physician assistants, nurses, nurse navigators, medical assistants, and other healthcare providers involved in the care of cancer patients.
Presented By
Commercial Support: Oncology 102: An In-Depth Hematology and Oncology Review for Advanced Practice Providers (On-Demand) Winter 2024 is supported in part by independent medical educational grants from Novocure, Inc., Merck Sharp & Dohme Corp., and Bristol Myers Squibb Company.
(01) Biomarker Testing 22:19 minutes (0.50 Credit)
» Rasheda Persinger, MS, AGNP-C, AOCNP - Johns Hopkins Sibley Memorial Hospital
(02) Patience and Understanding: Palliative Care for the APP 49:44 minutes (0.75 Credit)
» Alicia M. Rigby, MSN, RN, APRN, AOCNP - University of California, Davis
(03) Pain Management: An Integral Component of Caring for the Oncology Patient 61:44 minutes (1 Credit)
» Tanya Uritsky, PharmD, BCPP - University of Pennsylvania
(04) What is Chemotherapy 56:45 minutes (1 Credit)
» Sandra Cuellar, PharmD, BCOP, FHOPA, FASHP - University of Illinois College of Pharmacy
(05) Treating Melanoma in 2023: The Age of Immunotherapy and Targeted Therapy 32:27 minutes (0.50 Credit)
» Grace Cherry, NP - UCLA Health
(06) Identification and Management of Immune Related Adverse Events 37:24 minutes (0.50 Credit)
» Suzanne McGettigan, CRNP - Abramson Cancer Center
(07) Deciphering Radiation Oncology: A Deeper Dive into Acute and Late Effects from Treatment 29:33 minutes (0.50 Credit)
» Bridgett Harr, CNP - Cleveland Clinic
(08) Neuro-Oncology for the APP: What is Going on Up There? 32:52 minutes (0.50 Credit)
» Vanessa Nevins, PA-C, RDMS, RT - Yale New Haven Smilow Cancer Hospital
(09) Breast Oncology: Awareness and Current Knowledge 56:34 minutes (1 Credit)
» Kayla Freeman, DNP, APRN, FNP-C - Emory Winship Cancer Institute
(10) Gynecologic Malignancies: Clinical Pearls 28:49 minutes (0.50 Credit)
» Rachel Frankenthal, PA-C - UCLA Health
(11) Lung Cancer: Updates and Advancements 53:11 minutes (1 Credit)
» Beth Sandy, MSN, CRNP - University of Pennsylvania
(12) Updates in Treating and Managing Patients with Prostate, Bladder and Renal Cell Carcinoma 63:08 minutes (1 Credit)
» Brenda Martone, MSN, ANP-BC, AOCNP - Northwestern Medicine
» Laura S. Wood, RN, MSN, OCN - Cleveland Clinic
(13) Head and Neck Cancer: Diagnosis, Staging, and Management 55:46 minutes (1 Credit)
» Faith Mutale, DNP, CRNP - University of Pennsylvania
(14) Colorectal and Gastric Cancer: Current and Emerging Therapies 47:15 minutes (0.75 Credit)
» Nina Grenon, NP - Dana-Farber Cancer Institute
(15) A Deep Dive into Multiple Myeloma 69:22 minutes (1 Credit)
» Sara DiCamillo, PA-C, MPH - Winship Cancer Institute, Emory University
» Donna Catamero, ANP-BC, AOCN, CCRC - Icahn School of Medicine at Mount Sinai Hospital
(16) Advances in CLL and Follicular Lymphoma for the Clinical Oncology APP 59:07 minutes (1 Credit)
» Amy Goodrich, RN, MSN, CRNP - Johns Hopkins
(17) Understanding and Managing Acute Leukemia, Myelodysplastic Syndrome, and Myelofibrosis 45:46 minutes (0.75 Credit)
» Jennie M. Goble, PA-C - Mayo Clinic
(18) An Update of Current Treatment Options for Patients with Diffuse Large B-Cell Lymphoma 45:15 minutes (0.75 Credit)
» Christopher D'Andrea, PA-C - Cleveland Clinic
Planning Committee
Beth Faiman, PHD, MSN, APN-BC, AOCN, BMTCN, FAAN
Nurse Practitioner
Department of Hematology and Medical Oncology Cleveland Clinic
Cleveland, OH
Beth Sandy, MSN, CRNP
Nurse Practitioner, Thoracic Medical Oncology
Abramson Cancer Center, University of Pennsylvania
Philadelphia, PA
Ryan Beechinor, PharmD, BCPS, BCOP
Clinical pharmacist
UC Davis Comprehensive Cancer Center
San Francisco, CA
Leigh Ann Childress MSN, NP, AOCNP
Director of Advanced Practice
Clearview Cancer Institute
Huntsville, AL
Danielle Roberts PA-C
Physician assistant with the Bone Marrow Transplant team
Winship Cancer Institute of Emory University
Atlanta, GA
Faculty
Rasheda Persinger MS, AGNP-C, AOCNP
Lead Medical Oncology Nurse Practitioner
Johns Hopkins Sibley Memorial Hospital
Washington, DC
Alicia M. Rigby MSN, RN, APRN, AOCNP
Nurse Practitioner
UC Davis Cancer Center
Sacramento, CA
Tanya Uritsky PharmD, BCPP
Opioid Stewardship Coordinator
University of Pennsylvania (HUP)
Philadelphia, PA
Jennie M. Goble, PA-C
Instructor in Medicine
Mayo Clinic
Rochester, MN
Grace Cherry, NP
Nurse Practitioner
UCLA Health
Los Angeles, CA
Suzanne McGettigan CRNP
Oncology Nurse Practitioner and Clinical Manager of Advanced Practice Providers and Nursing
Perelman Center for Advanced Medicine, Abramson Cancer Center
Philadelphia, PA
Bridget Harr CNP
Nurse Practitioner
Cleveland Clinic
Cleveland, OH
Ellen Marin, PA-C
Physician Assistant
Winship Cancer Institute of Emory University
Atlanta, GA
Linda M. Perry, MS, PA-C
Physician Assistant
Perelman Center for Advanced Medicine
Philadelphia, PA
Meredith Beaton, MSN, RN, AG-ACNP
Nurse Practitioner
UCHealth Anschutz
Aurora, CO
Korie Bigbee DNP
Nurse Practitioner Specialist
Kaiser Permanente at City of Hope
Duarte CA
Kathleen Boyle, DScPAS, PA-C
Physician Assistant
Dana-Farber Cancer Institute
Boston, MA
Heather Koniarczyk, MSN, APRN-CNP, AOCNP
Adult Nurse Practitioner
Cleveland Clinic -Taussig Cancer Institute
Cleveland, OH
Jessica Walchonski, PA-C
Physician Assistant
UCLA Health
Los Angeles, CA
Grace Baek, PharmD, BCOP
Clinical Pharmacist, Hematology/Oncology
Fred Hutchinson Cancer Center
Seattle, WA
Sandra Cuellar, PharmD, BCOP, FHOPA, FASHP
Clinical Oncology Pharmacist
University of Illinois College of Pharmacy
Chicago, IL
Jennifer Murphy, PharmD, BCOP
Senior Pharmacist
UCD Health, Oncology, and Investigational Drug Service
San Francisco, CA
Laura Wood, RN, MSN, OCN
Nurse
Cleveland Clinic, Taussig Cancer Center
Cleveland, OH
Michael Lai, ARNP
Nurse Practitioner
Fred Hutchinson Cancer Center
Seattle, WA
Lisa Nodzon PhD, APRN, AOCNP
Nurse Practitioner
H. Lee Moffitt Cancer Center and Research Institute
Tampa, FL
Patricia Mangan, RN, MSN, CRNP
Nurse Lead, Hematologic Malignancies Program
Abramson Cancer Center,
University of Pennsylvania
Philadelphia, PA
DISCLOSURES:
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, Horizon CME (HCME) ensures that continuing education activities are balanced, independent, objective, and scientifically rigorous.
All persons in a position to influence the content of an accredited continuing education activity provided by Horizon CME are required to disclose to HCME any relevant financial relationships with ineligible companies within the past 24 months. All reported relevant financial relationships have been mitigated by Horizon CME.
Planners
Those others involved in the planning of this activity disclosed no relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.
Other Contributors
All other non-faculty contributors and others involved in the planning, development and editing/review of the content disclosed no relevant financial relationships with any entity producing, marketing, re-selling or distributing health care goods or services consumed by or used on patients.
Faculty, Authors, and Content Developers Disclosures:
• Rasheda Persinger, MS, AGNP-C, AOCNP discloses Advisory Board with AstraZeneca but that relationship has ended and Speaker's bureau with Guardant and Astra Zeneca and Advisory Boards, Consulting Fee's with AstraZeneca during the past 24 months.
• Sandra Cuehllar, PharmD, BCOP, FHOPA, FASHP discloses speaker's bureau with Mirati and Advisory Board with Genetech during the past 24 months.
• Suzanne McGettigan, CRNP discloses Speaker's Bureau with Regeneron, BMS, Pfizer, and Consulting Fee's with Merck during the past 24 months.
• Rachel Frankenthal, PA-C discloses Advisory Boards with ImmunoGenX, and GSK but that relationship has ended during the past 24 months.
• Laura S. Wood, RN, MSN, OCN discloses speaker's bureau with AVEO, BMS, EMD Serono, Exelixis, Merck, Pfizer during the past 24 months.
• Faith Mutale, DNP, CRNP discloses Speaker's Bureau, Services for Promotional purposes with Merck, Helsinn, Consulting Fee's with Merck, Pfizer, Helsinn, and Advisory Board with Pfizer during the past 24 months.
• Donna Catamero, ANP-BC, OCN, CCRC disclosed Speaker Bureau with BMS and GSK but that relationship has ended, Advisory Boards with Janssen Phar maceutical, Legend Biotech and Consulting Fee's with BMS during the past 24 months.
• Amy Goodrich, RN, MSN, CRNP discloses Advisory Board with BeiGene, Abbvie, AstraZeneca, Epizyme, Janssen, Sano during the past 24 months.
.
Planners:
• Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN discloses consulting fee's with Janssen, Sanofi, GSK, Pfizer during the past 24 months.
• Beth Sandy, MSN, CRNP discloses speaker's bureau with Merck, Amgen, Astra Zeneca, Lilly, Advisory Board with Takeda, Jazz, Janseen and Consulting Fee with Abbvie during the past 24 months.
• Leigh Ann Childress, MSN, NP, AOCNP discloses Advisory Board with Janssen but that relationship has ended and Speaker's Bureau with AstraZeneca , Seagen , Amgen , Merck during the past 24 months.
• Ryan Beechinor, PharmD, BCPS, BCOP discloses current consulting fee's with IQVIA, Cempra, ORM, Aptitude, Dedham and had contracted research with NIH and COG but that relationship has ended during the past 24 months.
• Beth Sandy, MSN, CRNP discloses speaker's bureau with Merck, Amgen, Astra Zeneca, Lilly, Advisory Board with Takeda, Jazz, Janseen and Consulting Fee with Abbvie during the past 24 months.
• Rachel Frankenthal, PA-C discloses Advisory Boards with ImmunoGenX, and GSK but that relationship has ended during the past 24 months.
Available Credit
- 14.00 AMA PRA Category 1 Credit™Horizon CME designates this Enduring activity for a maximum of 14.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 14.00 ANCCThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the American Nurses Credentialing Center’s Commission on Accreditation through the joint providership of the Nurse Practitioner Healthcare Foundation and Horizon CME. The Nurse Practitioner Healthcare Foundation is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. NPHF is awarding the contact hours and is responsible for adherence to the ANCC criteria. This course is approved by the Nurse Practitioner Healthcare Foundation, California Board of Registered Nursing, CEP# 16441. Upon completion, NPs and RNs will be awarded up to 14.00 credit.
- 2.25 PharmacologyThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the American Nurses Credentialing Center’s Commission on Accreditation through the joint providership of the Nurse Practitioner Healthcare Foundation and Horizon CME. The Nurse Practitioner Healthcare Foundation is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. NPHF is awarding the contact hours and is responsible for adherence to the ANCC criteria. This course is approved by the Nurse Practitioner Healthcare Foundation, California Board of Registered Nursing, CEP# 16441. Upon completion, NPs and RNs will be awarded up to 2.25 credit.
Price
Required Hardware/software
Access to the internet is required.
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above